New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Rosenberg, Eli S.; Holtgräve, David R.; Dorabawila, Vajeera; Conroy, MaryBeth; Greene, Danielle; Lutterloh, Emily; Backenson, Bryon; Hoefer, Dina; Morne, Johanne E.; Bauer, Ursula E.; Zucker, Howard A.

doi:10.15585/mmwr.mm7034e1

Cited by 198 publications

(156 citation statements)

References 6 publications

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…While we have adjusted for this by including them as covariates in the Cox model, the impact of this imbalance could potentially bias the results. Furthermore, there have recently been reports of declining VE against infection over time [14]. Although our methods should adjust for changes in underlying risks over time, such a decline may confound our analysis and bias the VE against Delta downwards, as most infections with the Delta variant occurred towards the end of follow-up in our study.…”

Section: Discussionmentioning

confidence: 95%

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

et al. 2021

View full text Add to dashboard Cite

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

show abstract

Section: Discussionmentioning

confidence: 95%

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Protection against COVID-19-associated hospitalization remained high despite the emergence of Delta as the predominant variant in the United States; protection was similar during periods before (February-June 2021; 84.1%) and during (July-August 2021; 89.3%) Delta variant predominance. Recent reports have shown that COVID-19 vaccine protection against SARS-CoV-2 infection is lower in areas with increasing Delta variant transmission (7,8); however, protection against severe disease outcomes, including hospitalization, remains high (7,9).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

Bajema¹,

Dahl²,

Prill³

et al. 2021

MMWR Morb. Mortal. Wkly. Rep.

102

View full text Add to dashboard Cite

this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly protective against COVID-19associated hospitalizations (1-3). Data are limited on the level of protection against hospitalization among disproportionately affected populations in the United States, particularly during periods in which the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, predominates (2). U.S. veterans are older, more racially diverse, and have higher prevalences of underlying medical conditions than persons in the general U.S. population (2,4). CDC assessed the effectiveness of mRNA vaccines against COVID-19associated hospitalization among 1,175 U.S. veterans aged ≥18 years hospitalized at five Veterans Affairs Medical Centers (VAMCs) during February 1-August 6, 2021. Among these hospitalized persons, 1,093 (93.0%) were men, the median age was 68 years, 574 (48.9%) were non-Hispanic Black (Black), 475 were non-Hispanic White (White), and 522 (44.4%) had a Charlson comorbidity index score of ≥3 (5). Overall adjusted vaccine effectiveness against COVID-19-associated hospitalization was 86.8% (95% confidence interval [CI] = 80.4%-91.1%) and was similar before (February 1-June 30) and during (July 1-August 6) SARS-CoV-2 Delta variant predominance (84.1% versus 89.3%, respectively). Vaccine effectiveness was 79.8% (95% CI = 67.7%-87.4%) among adults aged ≥65 years and 95.1% (95% CI = 89.1%-97.8%) among those aged 18-64 years. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated hospitalization in this older, racially diverse population of predominately male U.S. veterans. Additional evaluations of vaccine effectiveness among various age groups are warranted. To prevent COVID-19-related hospitalizations, all eligible persons should receive COVID-19 vaccination.

show abstract

“…After global transmission of the delta variant in June and July, 2021, reports describing reduced effectiveness of BNT162b2 (and other COVID-19 vaccines) against SARS-CoV-2 infections caused by the delta variant began to surface from Israel, 25 Qatar, 23 and the USA. 26 , 27 …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

et al. 2021

View full text Add to dashboard Cite

Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer–BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system. Methods In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov , NCT04848584 . Findings Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29–61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72–74) and against COVID-19-related hospital admissions was 90% (89–92). Effectiveness against infections declined from 88% (95% CI 86–89) during the first month after full vaccination to 47% (43–51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85–97]) but declined to 53% [39–65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95–99), but waned to 67% (45–80) at 4–5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84–96]) up to 6 months. Interpretation Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection. Funding Pfizer.

show abstract

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Cited by 198 publications

References 6 publications

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Contact Info

Product

Resources

About